Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

743 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. Stone RM, et al. Among authors: estey e. Ann Hematol. 2004;83 Suppl 1:S89-90. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124689 Clinical Trial. No abstract available.
Targeted therapy of AML new concepts.
Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Andreeff M, et al. Among authors: estey e. Ann Hematol. 2004;83 Suppl 1:S51-3. doi: 10.1007/s00277-004-0849-8. Ann Hematol. 2004. PMID: 15124670 No abstract available.
NCCN Practice Guidelines for Acute Myelogenous Leukemia.
Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS; National Comprehensive Cancer Network. Appelbaum FR, et al. Among authors: estey e. Oncology (Williston Park). 2000 Nov;14(11A):53-61. Oncology (Williston Park). 2000. PMID: 11195419 No abstract available.
Treatment of refractory AML.
Estey E. Estey E. Leukemia. 1996 Jun;10(6):932-6. Leukemia. 1996. PMID: 8667647 Review.
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M. Koller CA, et al. Among authors: estey e. Cancer. 1999 Dec 1;86(11):2246-51. doi: 10.1002/(sici)1097-0142(19991201)86:11<2246::aid-cncr11>3.0.co;2-i. Cancer. 1999. PMID: 10590364 Clinical Trial.
Value of routine 'day 14' marrow exam in newly diagnosed AML.
Yezefski T, Xie H, Walter R, Pagel J, Becker PS, Hendrie P, Sandhu V, Shannon-Dorcy K, Abkowitz J, Appelbaum FR, Estey E. Yezefski T, et al. Among authors: estey e. Leukemia. 2015 Jan;29(1):247-9. doi: 10.1038/leu.2014.268. Epub 2014 Sep 10. Leukemia. 2015. PMID: 25204570 No abstract available.
743 results